| 8.86 0.02 (0.23%) | 05-29 13:30 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.97 | 1-year : | 13.31 |
| Resists | First : | 10.25 | Second : | 11.39 |
| Pivot price | 9.18  |
|||
| Supports | First : | 8.39 | Second : | 6.98 |
| MAs | MA(5) : | 8.91 |
MA(20) : | 9.5 |
| MA(100) : | 11.48 |
MA(250) : | 10.01 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 22.2 |
D(3) : | 21.7 |
| RSI | RSI(14): 35.5 |
|||
| 52-week | High : | 14.51 | Low : | 6.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ARVN ] has closed above bottom band by 32.0%. Bollinger Bands are 22.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.06 - 9.15 | 9.15 - 9.2 |
| Low: | 8.58 - 8.7 | 8.7 - 8.77 |
| Close: | 8.71 - 8.89 | 8.89 - 9.01 |
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Fri, 22 May 2026
Arvinas (ARVN) CEO reports small automatic share sale for RSU tax withholding - Stock Titan
Wed, 20 May 2026
Arvinas (NASDAQ: ARVN) insider sells shares; RSU settlement reported - Stock Titan
Mon, 18 May 2026
Arvinas staff spend a day cooking, cleaning and crafting for patients and kids - Stock Titan
Sat, 16 May 2026
Analysts Just Published A Bright New Outlook For Arvinas, Inc.'s (NASDAQ:ARVN) - simplywall.st
Thu, 14 May 2026
Earnings Beat: Arvinas, Inc. (NASDAQ:ARVN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
Thu, 14 May 2026
Vanguard Group Inc. Sells 1,331,629 Shares of Arvinas, Inc. $ARVN - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 65 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 7.7 (%) |
| Held by Institutions | 83 (%) |
| Shares Short | 4,420 (K) |
| Shares Short P.Month | 4,510 (K) |
| EPS | -3.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6 |
| Profit Margin | -247.6 % |
| Operating Margin | -405.2 % |
| Return on Assets (ttm) | -19 % |
| Return on Equity (ttm) | -42.3 % |
| Qtrly Rev. Growth | -91.7 % |
| Gross Profit (p.s.) | 1.86 |
| Sales Per Share | 1.38 |
| EBITDA (p.s.) | -3.83 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -254 (M) |
| Levered Free Cash Flow | -200 (M) |
| PE Ratio | -2.8 |
| PEG Ratio | 0 |
| Price to Book value | 1.48 |
| Price to Sales | 6.4 |
| Price to Cash Flow | -2.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|